Cargando…
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising approach since blastic plasmacytoid dendritic...
Autores principales: | Philippe, Laure, Ceroi, Adam, Bôle-Richard, Elodie, Jenvrin, Alizée, Biichle, Sabeha, Perrin, Sophie, Limat, Samuel, Bonnefoy, Francis, Deconinck, Eric, Saas, Philippe, Garnache-Ottou, Francine, Angelot-Delettre, Fanny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664390/ https://www.ncbi.nlm.nih.gov/pubmed/28798071 http://dx.doi.org/10.3324/haematol.2017.169326 |
Ejemplares similares
-
BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020) -
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells
por: Caël, Blandine, et al.
Publicado: (2022) -
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
por: Zalmaï, Loria, et al.
Publicado: (2020) -
Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms
por: Roussel, Xavier, et al.
Publicado: (2022) -
Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?
por: Roggy, Anne, et al.
Publicado: (2021)